Publicaciones
Publicando las fronteras de la inmuno-oncología
Publicación destacada
Botensilimab (anti-CTLA-4 potenciado con FC), balstilimab (inhibidor de la PD-1)
Niveles emergentes de supervivencia con botensilimab y balstilimab: datos pantumorales de un amplio ensayo de fase 1b con tumores sólidos avanzados
May 31, 2026
,
Gordon y col.
ASCO
¡Gracias! ¡Su presentación ha sido recibida!
¡Uy! Algo salió mal al enviar el formulario.
¡Gracias! ¡Su presentación ha sido recibida!
¡Uy! Algo salió mal al enviar el formulario.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
First-line Botensilimab and Balstilimab OPtimization in Microsatellite Stable Colorectal Cancer without liver, bone, or brain metastasis
AACR
American Association for Cancer Research, Immuno-Oncology (AACR-IO)
February 26, 2025
,
DeVito et al.
Balstilimab (PD-1 inhibitor)
Biomarker analysis from phase 2 study of agenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)
AACR
American Association for Cancer Research, Immuno-Oncology (AACR-IO)
February 24, 2025
,
Cytryn et al.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Biomarker Analysis From a Phase II Study of AgenT-797 (invariant natural killer T cells) with Botensilimab (Fc-enhanced CTLA-4 inhibitor) and Balstilimab (anti-PD-1) in PD-1 Refractory Gastroesophageal Cancer
AACR
American Association for Cancer Research, Immuno-Oncology (AACR-IO)
February 24, 2025
,
Cytryn et al.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Other Articles & Publications
Journal of Clinical Oncology
February 14, 2025
,
Wilky et al.
Agenus Inc.
3 Forbes Road
Lexington, Massachusetts 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200
3 Forbes Road
Lexington, Massachusetts 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200